BBOT
NASDAQ · Biotechnology
Bridgebio Oncology Therapeut
$9.33
+0.55 (+6.26%)
Open$8.91
Previous Close$8.78
Day High$9.42
Day Low$8.89
52W High$14.87
52W Low$7.00
Volume—
Avg Volume265.6K
Market Cap703.34M
P/E Ratio—
EPS$-2.30
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+362.0% upside
Current
$9.33
$9.33
Target
$43.10
$43.10
$22.76
$43.10 avg
$48.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 230.06M | 225.69M | 230.96M |
| Net Income | 46.84M | 61.14M | 59.73M |
| Profit Margin | 20.4% | 27.1% | 25.9% |
| EBITDA | 108.29M | 111.55M | 110.87M |
| Free Cash Flow | 56.78M | 36.61M | 55.99M |
| Rev Growth | -2.3% | +22.3% | +7.3% |
| Debt/Equity | 0.31 | 0.27 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |